ReviewAddiction (Abingdon, England)2010
Cognitive enhancement as a pharmacotherapy target for stimulant addiction.
Review in Addiction (Abingdon, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Regional differences in white matter integrity in stimulant use disorders: A meta-analysis of diffusion tensor imaging studies.Drug and alcohol dependence · 2019Pooled it
- Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder.Journal of substance abuse treatment · 2019Trial
- Working Memory Training in Alcohol Use Disorder: A Randomized Controlled Trial.Alcoholism, clinical and experimental research · 2019Trial
- Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.Pharmacology, biochemistry, and behavior · 2017Trial
- Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder.The international journal of neuropsychopharmacology · 2015Trial
- Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.Drug and alcohol dependence · 2014Trial
- Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers.Progress in neuro-psychopharmacology & biological psychiatry · 2014Trial
- The effects of acute abstinence from smoking and performance-based rewards on performance monitoring.Psychopharmacology · 2013Trial
- Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects.Journal of psychopharmacology (Oxford, England) · 2013Trial
- Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Relationship of age to impulsivity and decision making: a baseline secondary analysis of a behavioral treatment study in stimulant use disorders.Journal of addictive diseases · 2013Trial
- Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study.Drug and alcohol dependence · 2012Trial
- The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.Psychopharmacology · 2012Trial
- Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Trial
- Galantamine improves sustained attention in chronic cocaine users.Experimental and clinical psychopharmacology · 2011Trial
- Impulsivity is associated with treatment non-completion in cocaine- and methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis.Journal of substance abuse treatmentTrial
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- OptimizedJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
- Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder - a longitudinal structural magnetic resonance imaging study.Translational psychiatry · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundNo medications have been proven to be effective for cocaine and methamphetamine addiction. Attenuation of drug reward has been the main strategy for medications development, but this approach has not led to effective treatments. Thus, there is a need to identify novel treatment targets in addition to the brain reward system.
aimTo propose a novel treatment strategy for stimulant addiction that will focus on medications enhancing cognitive function and attenuating drug reward.
methodsPre-clinical and clinical literature on potential use of cognitive enhancers for stimulant addiction pharmacotherapy was reviewed. RESULTS AND
conclusionsCocaine and methamphetamine users show significant cognitive impairments, especially in attention, working memory and response inhibition functions. The cognitive impairments seem to be predictive of poor treatment retention and outcome. Medications targeting acetylcholine and norepinephrine are particularly well suited for enhancing cognitive function in stimulant users. Many cholinergic and noradrenergic medications are on the market and have a good safety profile and low abuse potential. These include galantamine, donepezil and rivastigmine (cholinesterase inhibitors), varenicline (partial nicotine agonist), guanfacine (alpha(2)-adrenergic agonist) and atomoxetine (norepinephrine transporter inhibitor). Future clinical studies designed optimally to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these cognitive enhancers for stimulant addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.